Dr. Reddy's Laboratories Limited
As of Oct 16, 2026 close
- Market cap
- $10.75B
- P/E (TTM)
- 31.70
- Forward P/E
- 55.86
- Dividend yield
- 1.14%
- 52-week range
- $11.36$15.67
- Volume (live)
- -
- Avg. volume (3M)
- 2.94M
Dr. Reddy's Laboratories (RDY) Stock Price & Financial Analysis
Dr. Reddy's Laboratories Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $12.94 - $13.07 |
|---|---|
| 52-Week High | $15.67 |
| 52-Week Low | $11.36 |
| Open | $13.00 |
| Volume (last close) | 2.79M |
| Average Volume (3M) | 2.94M |
| Revenue (TTM) | 3.50B |
|---|---|
| Net Income (TTM) | 339.26M |
| Free Cash Flow (TTM) | 97.01M |
| EPS (TTM) | $0.41 |
| Profit Margin | 9.70% |
| Operating Margin | 10.12% |
| Return on Equity (ROE) | 8.34% |
| Debt to Equity | 0.18 |
| Annual Dividend | $0.15 |
|---|---|
| Dividend Yield | 1.14% |
| Payout Ratio | 36.29% |
| Last Dividend Ex-Date | Jul 24, 2026 |
| Market Cap | 10.75B |
|---|---|
| Shares Outstanding | 833.65M |
| P/E Ratio (TTM) | 31.70 |
| Forward P/E | 55.86 |
| Price to Sales (P/S) | 3.07 |
| Price to Book (P/B) | 2.64 |
| EV/EBITDA | 17.87 |
| 50-Day MA | $12.24 |
|---|---|
| 200-Day MA | $13.23 |
| 1-Year Change | −10.73% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Dr. Reddy's Laboratories at a Glance
As of the Oct 16, 2026 close, Dr. Reddy's Laboratories (RDY) has a market capitalization of $10.75B. The stock trades at 31.7× trailing earnings, 55.9× forward earnings and 3.1× sales. Over the trailing twelve months it earned $339.26M on revenue of $3.50B (a 9.7% profit margin) and generated $97.01M of free cash flow. Revenue fell 0.9% year over year.
As of its latest reported balance sheet, it holds $117.90M in cash and securities against $732.13M of debt, a net debt position of $614.22M.
Dr. Reddy's Laboratories pays a annual dividend totaling $0.15 per share a year, a 1.14% yield at the Oct 16, 2026 close, with a 36% payout ratio.
The share price is down 10.7% over the past year. At $13.07 (the Oct 16, 2026 close) it sits within its 52-week range of $11.36 to $15.67, below its 200-day moving average of $13.23.
Frequently Asked Questions About Dr. Reddy's Laboratories
What is the current stock price for RDY?
As of the Oct 16, 2026 close, RDY stock trades at $13.07. The 52-week range is $11.36–$15.67, with a day range of $12.94–$13.07.
What is the P/E ratio for RDY?
As of the Oct 16, 2026 close, Dr. Reddy's Laboratories's trailing twelve-month (TTM) P/E ratio is 31.7, meaning investors pay $31.7 for every $1 of annual earnings. The forward P/E is 55.9, reflecting analyst expectations for future earnings. Dr. Reddy's Laboratories operates in the Healthcare sector.
Does RDY pay dividends?
Yes, Dr. Reddy's Laboratories pays a 1.14% annual dividend yield as of the Oct 16, 2026 close ($0.15 per share a year). The trailing twelve-month payout ratio is 36.3%. The most recent ex-dividend date was July 24, 2026.
What do analysts recommend for RDY?
Analyst ratings and recommendations for RDY are displayed in the Analyst Consensus section, including buy/hold/sell distribution and 12-month price targets.
What is the market cap of RDY?
As of the Oct 16, 2026 close, Dr. Reddy's Laboratories's market capitalization is $10.90B, classifying it as a large-cap company. Dr. Reddy's Laboratories operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.